PD-166793 Inhibitor

PD-166793 is a cell-permeable biphenylsulfonylvaline compound. It is an inhibitor against MMP-2, MMP-3, and MMP-13 (IC50s: 47, 12, and 8nM). PD-166793 is also a weaker inhibitor against AMP deaminase (20% inhibition at 0.1uM), MMP-1, MMP-7, MMP-9, and MMP-14 (IC50s: 6.1, 7.2, 7.9, and 0.24uM).

Kaludercic N, Lindsey ML, Tavazzi B, Lazzarino G, Paolocci N. Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond. Cardiovasc Ther. 2008 Spring;26(1):24-37. doi: 10.1111/j.1527-3466.2007.00034.x. Review. PubMed PMID: 18466418.
Mendes O, Kim HT, Stoica G. Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis. 2005;22(3):237-46. PubMed PMID: 16158251.
Wang W, Sawicki G, Schulz R. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res. 2002 Jan;53(1):165-74. PubMed PMID: 11744025.
Chancey AL, Brower GL, Peterson JT, Janicki JS. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation. 2002 Apr 23;105(16):1983-8. PubMed PMID: 11997287.

Small volumes of PD-166793, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5756470 is an inhibitor targeting PD-166793.